C Allison Stewart
Overview
Explore the profile of C Allison Stewart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morris B, Heeke S, Xi Y, Diao L, Wang Q, Rocha P, et al.
bioRxiv
. 2024 Aug;
PMID: 39211077
Introduction: A hallmark of small cell lung cancer (SCLC) is its recalcitrance to therapy. While most SCLCs respond to frontline therapy, resistance inevitably develops. Identifying phenotypes potentiating chemoresistance and immune...
2.
Stewart C, Diao L, Xi Y, Wang R, Ramkumar K, Serrano A, et al.
Clin Cancer Res
. 2024 Aug;
30(20):4743-4754.
PMID: 39150543
Purpose: Large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine malignancy that, like small cell lung cancer (SCLC), is associated with the absence of druggable oncogenic drivers and dismal prognosis....
3.
Zhang B, Lewis W, Stewart C, Morris B, Solis L, Serrano A, et al.
JTO Clin Res Rep
. 2024 Feb;
5(2):100623.
PMID: 38357092
Introduction: NSCLC transformation to SCLC has been best characterized with -mutant NSCLC, with emerging case reports seen in , , and -altered NSCLC. Previous reports revealed transformed SCLC from -mutant...
4.
Ramkumar K, Tanimoto A, Della Corte C, Stewart C, Wang Q, Shen L, et al.
Clin Cancer Res
. 2023 Jun;
29(16):3237-3249.
PMID: 37289191
Purpose: Therapeutic resistance to frontline therapy develops rapidly in small cell lung cancer (SCLC). Treatment options are also limited by the lack of targetable driver mutations. Therefore, there is an...
5.
Zhang B, Stewart C, Wang Q, Cardnell R, Rocha P, Fujimoto J, et al.
Br J Cancer
. 2022 Apr;
127(3):569-576.
PMID: 35440668
Introduction: Small cell lung cancer (SCLC) is an aggressive malignancy with no established biomarkers. Schlafen 11(SLFN11), a DNA/RNA helicase that sensitises cancer cells to DNA-damaging agents, has emerged as a...
6.
Stewart C, Stewart M, Wang Y, Mullen R, Kircher B, Liang R, et al.
Endocrinology
. 2022 Feb;
163(3).
PMID: 35134138
Female mice homozygous for an engineered Gnrhr E90K mutation have reduced gonadotropin-releasing hormone signaling, leading to infertility. Their ovaries have numerous antral follicles but no corpora lutea, indicating a block...
7.
Kundu K, Cardnell R, Zhang B, Shen L, Stewart C, Ramkumar K, et al.
Transl Lung Cancer Res
. 2022 Jan;
10(11):4095-4105.
PMID: 35004241
Background: Lurbinectedin recently received FDA accelerated approval as a second line treatment option for metastatic small cell lung cancer (SCLC). However, there are currently no established biomarkers to predict SCLC...
8.
Cargill K, Stewart C, Park E, Ramkumar K, Gay C, Cardnell R, et al.
Cancer Metab
. 2021 Sep;
9(1):33.
PMID: 34556188
Introduction: The transcription factor MYC is overexpressed in 30% of small cell lung cancer (SCLC) tumors and is known to modulate the balance between two major pathways of metabolism: glycolysis...
9.
Zhang B, Ramkumar K, Cardnell R, Gay C, Stewart C, Wang W, et al.
Br J Cancer
. 2021 Jul;
125(10):1333-1340.
PMID: 34294893
DNA-damaging agents exploit increased genomic instability, a hallmark of cancer. Recently, inhibitors targeting the DNA damage response (DDR) pathways, such as PARP inhibitors, have also shown promising therapeutic potential. However,...
10.
Stewart C, Gay C, Ramkumar K, Cargill K, Cardnell R, Nilsson M, et al.
J Thorac Oncol
. 2021 Jul;
16(11):1821-1839.
PMID: 34274504
Introduction: Coronavirus disease 2019 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which enters host cells through the cell surface proteins ACE2 and TMPRSS2. Methods:...